Aridis Pharmaceuticals Inc (ARDS) Given $28.25 Consensus Target Price by Analysts

Share on StockTwits

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus price objective of $28.25 for the company and are expecting that the company will post ($1.03) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aridis Pharmaceuticals an industry rank of 90 out of 255 based on the ratings given to related companies.

A number of brokerages recently commented on ARDS. Maxim Group began coverage on shares of Aridis Pharmaceuticals in a research note on Tuesday, October 2nd. They issued a “buy” rating for the company. Northcoast Research began coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They issued an “outperform” rating and a $40.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They issued an “overweight” rating for the company. Northland Securities began coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They issued an “outperform” rating for the company. Finally, Laidlaw began coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They issued a “buy” rating and a $23.00 price objective for the company.

Shares of Aridis Pharmaceuticals stock traded up $0.04 on Thursday, hitting $12.64. 600 shares of the company traded hands, compared to its average volume of 16,622. Aridis Pharmaceuticals has a 52 week low of $11.25 and a 52 week high of $13.85.

Aridis Pharmaceuticals Company Profile

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

See Also: Why does a company issue an IPO?

Get a free copy of the Zacks research report on Aridis Pharmaceuticals (ARDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.